NYSE

Novo Nordisk A S

NVO

10 stories

$176B Market cap · 2026-10-30

Get NVO news in Claude, ChatGPT or your own code. See plans

@BarbarianCap 16h ago 1 click

Barbarian Capital on X

Novo sales boosted by Wegovy weight-loss pill $NVO https://t.co/k6UtmXHO3L

Novo Nordisk (NVO) Q3 FY 12/26 Earnings Review

Novo Nordisk beat Q3 consensus as Wegovy pill sales reached DKK 5.4bn, raised 2026 guidance again and reported DKK 79.2bn revenue.

NVO $176B

Cestrian Capital Research 23h ago 5 clicks

From Fat to Follicles - Is Hair Loss the Next Blockbuster?

Novo Nordisk has only floated hair loss, while Veradermics’ Phase 3 oral minoxidil data lead a field of licensing and takeover candidates.

NVO $176BMANE $5.6B

Cestrian Capital Research Oct 20 41 clicks

GLP-1 winners and losers

GLP-1 drugs are gaining traction across Asia as Chinese developers advance candidates and Indian generics slash prices, reshaping prospects…

NVO $176B

Asian Century Stocks Sep 14 3 clicks

NVO 2026-08-22

Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk

Eli Lilly holds 60–61% of the US obesity-drug market as prescriptions and international expansion offset pricing pressure from Novo Nordisk.

NVO $176BLLY $1.3T

JR Research Aug 22 2 clicks

Novo Nordisk Q2 2026 Review: Better Than Feared But Is It Enough?

Novo Nordisk’s Q2 adjusted sales rose 7% and operating profit 11%, prompting a 0% to -6% 2026 outlook as commercial recovery outpaces…

NVO $176B

Hated Moats Aug 7

@BrokenMoats Jun 10

Broken Moats on X

$LLY has nlrp3 trials so that would just put them in the same conversation no with a head start? Agree its valuable to NVO but wouldn't the derivatives like a $BIOA get more juice of ZEUS then $NVO from validating the space. I like NVO but management shoots themselves in the foot constantly and AZN etc competition on weight loss is coming